R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Dr Jörg Schüttrumpf, Chief Scientific Innovation Officer of Grifols, discusses advancing immunoglobulin (or IG) treatment for immune disorders.

R&D

The second half of 2025 showed pharma and healthcare leaning into partnerships that de‑risk innovation and compress time to market.

R&D

AI is being used from protocol design to study start-up and through clinical trial closeout, reshaping the trial lifecycle.

R&D

Through focused strategies and industry collaboration, labs can significantly reduce waste, energy usage, and emissions.

R&D

Using IP intelligence to guide R&D activity can also help companies to develop treatments that are more effective, with fewer side effects.

R&D

Markus Vossman, Germany general manager at Illumina, discusses innovative genomic applications and projects in the region.